Grant ID RP240287
Awarded On February 21, 2024
Title Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Hussein Abbas
Cancer Sites Leukemia
Contracted Amount $1,042,256*

*Pending contract negotiation

Lay Summary

Acute Myeloid Leukemia (AML) is a challenging cancer of the blood. Venetoclax is a common treatment in AML that improved outcomes. The prognosis for patients after relapse is extremely poor, with survival typically limited to a few months. Our goal is to uncover why this happens and to develop new strategies to prevent therapy resistance and relapse, thereby enhancing patient survival. To do this, we need to understand how AML cells reshape its environment. Our preliminary work shows a strong link between a specific inflammation signal, known as interferon gamma, and resistance to venetoclax. The same signal also turns AML cells into more primitive cells that are known for resisting treatmen...

Read More